UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of February 2018
 
Commission File Number: 001-36187

EVOGENE LTD.
  (Translation of Registrant’s Name into English)
 
13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F ☒ Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 

 
CONTENTS
 
Attached hereto and incorporated by reference herein is the following exhibit:
 
99.1
Press Release: Evogene Announces Positive Results in its Novel Mode-of-Action Herbicide Program.
 


 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 



Date: February 27, 2018
 
EVOGENE  LTD.
(Registrant)

By: /s/ Alex Taskar

Alex Taskar
Chief Financial Officer


 
EXHIBIT INDEX
 
EXHIBIT NO.
DESCRIPTION
 
 


Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Evogene Charts.
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Evogene Charts.